Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention.
about
G-protein-coupled receptors signaling pathways in new antiplatelet drug developmentComparative evaluation of direct thrombin and factor Xa inhibitors with antiplatelet agents under flow and static conditions: an in vitro flow chamber modelBivalirudin as a bridge for anticoagulation in high risk neurosurgical patients with active DVT or high risk of thrombosis.The Phosphatase Inhibitor Calyculin-A Impairs Clot Retraction, Platelet Activation, and Thrombin Generation.Distinct effects of unfractionated heparin versus bivalirudin on circulating angiogenic peptides.Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin.Allosteric Activation of a G Protein-coupled Receptor with Cell-penetrating Receptor MimeticsCell-Penetrating Pepducin Therapy Targeting PAR1 in Subjects With Coronary Artery Disease.Noncanonical matrix metalloprotease-1-protease-activated receptor-1 signaling triggers vascular smooth muscle cell dedifferentiation and arterial stenosis.Relative efficacy of bivalirudin versus heparin monotherapy in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: a network meta-analysisDichotomous effects of exposure to bivalirudin in patients undergoing percutaneous coronary intervention on protease-activated receptor-mediated platelet activation.Serine and metalloprotease signaling through PAR1 in arterial thrombosis and vascular injury.Almanac 2013: acute coronary syndromes.Developing drugs for use before, during and soon after percutaneous coronary intervention.Intracoronary Bivalirudin Bolus in ST-Elevation Myocardial Infarction Patients Treated with Primary Angioplasty: Theoretical Bases, Clinical Experience, and Future Applications.Pepducins and Other Lipidated Peptides as Mechanistic Probes and Therapeutics.Exploring potential anticoagulant drug formulations using thrombin generation test.Comparison of bivalirudin versus heparin(s) during percutaneous coronary interventions in patients receiving prasugrel: a propensity-matched study.Phosphatidylinositol transfer protein-α in platelets is inconsequential for thrombosis yet is utilized for tumor metastasis.The effect of differing pharmacologic strategies on infarct size in primary PCI--more confirmatory data for bivalirudin.Antithrombotic efficacy of bivalirudin compared to unfractionated heparin during percutaneous coronary intervention for acute coronary syndrome.Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis.
P2860
Q26864951-E1857DDA-DFBE-486E-9B31-47EB21974880Q27330363-0084DB8D-3FB9-4B46-9A77-4A06CEDC8E89Q33406950-0BB7B1A4-640F-4671-80C7-181D59BDCBA0Q33819944-75C535BE-5D99-47A6-8F50-B0054BFC1359Q34235153-3CA79318-E30C-45AD-B6EC-6F2AF77EAD00Q34282119-EDDA8ADF-A74A-432A-B68E-F9111FBFCD7FQ35860717-B2176980-8B6F-4629-AC9E-34C7DA0B752AQ36813106-59E5782B-2E61-4931-A9BD-885AF1C3AA68Q37095396-825A18B8-5E75-42A7-8A3D-1F469CADE7D5Q37225552-1F3AED21-AD78-412A-9129-280AEB41C1F0Q37671483-7609A0A3-6330-4EF2-B31D-9E621428466CQ37873891-BEF15F97-F19E-46DA-A16F-7DFD2AAB8705Q38128939-FDB7C3D5-297D-48DE-BAEA-177EC7061CF3Q38708145-D3D88BE9-F12A-42A6-A4C6-C763A3881BEAQ38829835-A3F050C3-2F51-4314-A04B-C2BB85189D72Q40405065-29E60FA6-35E8-49A6-96E2-B2FA16CE0620Q41683411-8C3B228C-5FE7-4AB7-898E-F54BB09573ACQ45783706-16AD6364-C233-47EA-BC1C-B943B81E01FDQ47096471-B87E9938-D5D2-404F-A989-0CEA4FE0BDA0Q47305352-AACF995C-6E62-44D9-8A9A-F0730FBEAC1CQ49666836-B6FE5813-35D7-4745-90EA-F349E8C61F02Q52721277-AB0B1AF6-8221-4EEE-B4FC-2F91A1A910AC
P2860
Bivalirudin is a dual inhibitor of thrombin and collagen-dependent platelet activation in patients undergoing percutaneous coronary intervention.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Bivalirudin is a dual inhibito ...... taneous coronary intervention.
@ast
Bivalirudin is a dual inhibito ...... taneous coronary intervention.
@en
Bivalirudin is a dual inhibito ...... taneous coronary intervention.
@nl
type
label
Bivalirudin is a dual inhibito ...... taneous coronary intervention.
@ast
Bivalirudin is a dual inhibito ...... taneous coronary intervention.
@en
Bivalirudin is a dual inhibito ...... taneous coronary intervention.
@nl
prefLabel
Bivalirudin is a dual inhibito ...... taneous coronary intervention.
@ast
Bivalirudin is a dual inhibito ...... taneous coronary intervention.
@en
Bivalirudin is a dual inhibito ...... taneous coronary intervention.
@nl
P2093
P2860
P1476
Bivalirudin is a dual inhibito ...... taneous coronary intervention.
@en
P2093
Andrew Weintraub
Athan Kuliopulos
Barath Krishnamurthy
Carey Kimmelstiel
Lidija Covic
Navin K Kapur
Ping Zhang
Vilma Castaneda
P2860
P304
P356
10.1161/CIRCINTERVENTIONS.110.959098
P577
2011-03-01T00:00:00Z